Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | V31I |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | TP53 V31I lies within the CCAR2 and HRMT1L2-interacting regions and the transcription activation region of the Tp53 protein (UniProt.org). V31I results in colony growth, induction of apoptosis, and transcriptional activity similar to wild-type Tp53 in cultured cells (PMID: 33257846), and therefore, is predicted to have no effect on Tp53 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 V31I |
Transcript | NM_000546.6 |
gDNA | chr17:g.7676387C>T |
cDNA | c.91G>A |
Protein | p.V31I |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126112.2 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7676387C>T | c.91G>A | p.V31I | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|